

NIMHD Fiscal Year 2013 Financial Management Plan for Grant Awards

Under the Consolidated and Further Continuing Appropriations Act, 2013 (P.L. 113-6), signed by President Obama on March 26, 2013, and the sequestration provisions of the Balanced Budget and Emergency Deficit Control Act, as amended, 2 U.S.C. § 901a, NIH and NIMHD have established their financial management plans for grant awards. The NIMHD full-year appropriation was reduced by about 5 percent compared to FY 2012.

Research Project Grants (RPGs)

- Noncompeting RPGs: Noncompeting continuation awards will be funded at 93.5% of the FY 2013 committed level. Commitments for continuation awards in FY 2014 and beyond will remain unchanged. FY 2013 noncompeting awards that have already been issued at a reduced level will be revised upward to reflect this funding level.
- Competing RPGs: NIMHD will make an effort to keep the average size of competing awards constant at FY 2012 levels but is likely to make fewer competing awards in FY 2013.

SBIR/STTR

- The SBIR/STTR Reauthorization Act of 2011 mandates an increase to this set-aside. For FY 2013, NIMHD will increase the set-aside to 3.15 percent. Noncompeting continuation awards will be funded at 100% of the FY 2013 committed level. FY 2013 noncompeting awards that have already been issued at a reduced level will be revised upward to reflect this funding level.

Centers and Other Mechanisms

- Noncompeting continuation awards will be funded at 93.5% of the FY 2013 committed level. Commitments for continuation awards in FY 2014 and beyond will remain unchanged. FY 2013 noncompeting awards that have already been issued at a reduced level will be revised upward to reflect this funding level.

Inflationary Increases for Future Years

- Inflationary increases for future year commitments will be discontinued for all competing research grant awards issued in FY 2013.

New Investigators

- NIMHD will continue to support new investigators on Type 1 (new) R01 equivalent awards at a success rate comparable to that of established investigators submitting Type 1 applications.